ClinicalTrials.gg
RecruitingNCT05868993Updated May 22, 2023

Optimal Effective Local Anesthetic Volume for Pain Relief Using Brachial Plexus Block

A Phase 4 interventional study of Dose of 0.5% Ropivacaine in Post Operative Pain, sponsored by Benaroya Research Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by Benaroya Research Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Planned enrollment
236th of 1,099
150 · median 76
Started
2023
with 54 others
Phase 4
359 of 1,181
72 open now
Primary completion
2025-02
later than 17 of 236 live
Registered
965th of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 236th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 55 that started in 2023, is one of 359 in phase 4, reaches primary completion later than 17 of the 236 other live ones, and was the 965th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

199 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

Prospective, patient-blinded study utilizing a novel Continuous Reassessment Method that concomitantly considers both block success and block side effects (lung dysfunction) for brachial plexus nerve blocks.

Read the detailed description

Success or failure of the brachial plexus block for any given volume will be determined by the verbal analogue pain scale score obtained 60 minutes after surgical end time. Volumes will be determined by continuous reassessment method.

03

Conditions studied

  • Post Operative Pain

Browse trials for

Keywords

  • brachial plexus block
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgical candidate for Arthroscopic rotator cuff surgery
  • \<40
  • Age >18

Exclusion criteria

Exclusion Criteria:

  • Inability to give
  • Inability to complete consent process in English
  • allergy to ropivacaine
  • neuropathy
  • to peripheral nerve block per ASRA guidelines
  • chronic opioid use
  • infection at the injection/catheter site
  • limb restriction due to medical history
  • history of moderate - severe lung disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Brachial Plexus Block Group 1

    Interscalene

    Drug: Dose of 0.5% Ropivacaine

  • Experimental
    Brachial Plexus Group 2

    Supraclavicular

    Drug: Dose of 0.5% Ropivacaine

  • Experimental
    Brachial Plexus Group 3

    Suprascapular

    Drug: Dose of 0.5% Ropivacaine

Interventions

  • DrugDose of 0.5% Ropivacaine

    Dose varied by 5mL of 0.5% Ropivacaine

06

What researchers measure

Primary outcomes

  1. Block Success

    Block success measured by pain (11-point VAS)

    Time frame: 60min after surgery

  2. Lung Function

    Block success as measured by preservation of lung function (Vital Capacity in L)

    Time frame: 60 mins after surgery

  3. Block Success

    Block Success measured by opioid (mcg of fentanyl delivered)

    Time frame: 60 mins after surgery

Secondary outcomes

  1. Diaphragm Excursion

    Change in Movement of Diaphragm in cm

    Time frame: 60 minutes after surgery

  2. Vital Capacity

    Change in Vital Capacity measured in L

    Time frame: 60 minutes after surgery

  3. Pulse Oximetry

    Change in Pulse Oximetry Value

    Time frame: 60 minutes after surgery

  4. Side Effects

    Rate of Dyspnea, Horner's, Hoarseness

    Time frame: 60 minutes after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2025, 24 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 24 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
May 22, 2023
StartActual
Feb 17, 2023
Primary completionEst.
Feb 2025
CompletionEst.
Dec 2025
Last update
May 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05868993
Lead sponsor
Benaroya Research Institute
Responsible party
Sponsor
First posted
May 22, 2023
Start date
Feb 17, 2023
Primary completion
Feb 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
May 22, 2023

Study contacts

David Auyong
Contact
anedba@vmmc.org
206-223-6980

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion